International Journal of Drug Delivery Technology
Volume 14, Issue 3

Prescribing Pattern of Antidiabetic Drugs and Its Adherence to American Diabetes Association Guidelines in Patients of Type 2 Diabetes Mellitus with and Without Comorbidities

Amin SS*, Jogdand SD

Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India. 

Received: 05th August, 2024; Revised: 17th August, 2024; Accepted: 26th August, 2024; Available Online: 25th September, 2024 

ABSTRACT

Diabetes mellitus is a persistent metabolic illness defined by high amounts of glucose in the blood, and it presents a substantial worldwide health problem. The incidence of diabetes is escalating at a quick pace as a result of variables including urbanization, lack of exercise and changing dietary patterns, particularly in developing countries where undiagnosed cases are prevalent. This review examines the prescription patterns of antidiabetic drugs for type 2 diabetes mellitus patients (T2DM), both with and without comorbidities, and evaluates adherence to the American Diabetes Association (ADA) guidelines. Effective management of T2DM is critical to preventing complications, but poor medication adherence remains a significant issue, leading to adverse outcomes and high healthcare costs. This review analyzes commonly prescribed oral hypoglycemic agents, their mechanisms of action, and side effects and discusses the importance of managing T2DM to prevent microvascular and macrovascular complications.

Challenges in adhering to ADA guidelines include lack of awareness, physical and architectural barriers, effective communication, and financial constraints. Addressing these challenges through multidisciplinary care, continuous medical education, and comprehensive public health interventions is essential for improving patient outcomes and mitigating the global diabetes epidemic.

Keywords: Type 2 Diabetes Mellitus, Antidiabetic drugs, Prescription patterns, ADA guidelines. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.90

How to cite this article: Amin SS, Jogdand SD. Prescribing Pattern of Antidiabetic Drugs and Its Adherence to American Diabetes Association Guidelines in Patients of Type 2 Diabetes Mellitus with and Without Comorbidities. International Journal of Drug Delivery Technology. 2024;14(3):1908-1913.

REFERENCES

  1. Lović D, Piperidou A, Zografou I, Grassos H, Pittaras A, ManolisThe growing epidemic of diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):104-109. Available from: https://doi.org/ 10.2174/1570161117666190405165911
  2. Shaw JE, Sicree R, Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14. Available from: https://doi.org/10.1016/j. diabres.2009.10.007
  3. Mohan V, Pradeepa Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932-2932. Available from: https://doi.org/10.4103/ijo.ijo_1627_21
  4. Blackburn D, Swidrovich J, Lemstra Nonadherence in type 2
  5. diabetes: practical considerations for interpreting the literature. Patient Prefer Adherence. 2013;183-183. Available from: https:// doi.org/10.2147/ppa.s30613
  6. Currie CJ, Peyrot M, Morgan CL, Poole C, Jenkins-Jones S, Rubin RR, et The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279-1284. Available from: https://doi.org/10.2337/ dc11-1277
  7. Chang CT, Ching LC, Hanafiah R. The impact of pharmacist interventions, follow-up frequency and default on glycemic control in diabetes medication therapy adherence clinic program: a multicenter study in Malaysia. BMC Health Serv 2023;16(1). Available from: https://doi.org/10.1186/s40545- 023-00583-8
  8. Nickerson H, Dutta Diabetic complications: Current challenges and opportunities. Curr Atheroscler Rep. 2012;5(4):375-379. Available from: https://doi.org/10.1007/s12265-012-9388-1
  9. Ogurtsova K, Fernandes JDDR, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50. Available from: http://diabetesresearchclinicalpractice.com/retrieve/pii/ S0168822717303753
  10. Shaw JE, Sicree R, Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14. Available from: https://doi.org/10.1016/j. diabres.2009.10.007
  11. Swami OC, Sharma SK, Panneerselvam A, Singh K, Parmar G, Gadge Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:251-260. Available from: https://doi.org/10.2147/dmso.s106133
  12. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune Curr Pharm Des. 2020;16(5):442-449. Available from: https://doi.org/10.2174/157 3399815666191024085838
  13. Diabetes Congress 2023. Allied Academies. 2022. Available from: https://diabetes.alliedacademies.com/
  14. Rahimi R, Nikfar S, Larijani B, Abdollahi A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59(7):365-373. Available from: https://doi.org/10.1016/j.biopha.2005.07.002
  15. Katakami N. Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. J Atheroscler 2018;25(1):27-39. Available from: https://doi.org/10.5551/ jat.rv17014
  16. Alicic RZ, Rooney MN, Tuttle Diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12(1):203-220. Available from: https:// doi.org/10.2215/cjn.11491116
  17. Blackburn D, Swidrovich J, Lemstra Nonadherence in type 2 diabetes: Practical considerations for interpreting the literature. Patient Prefer Adherence. 2013;7:183-190. Available from: https:// doi.org/10.2147/ppa.s30613
  18. Swami OC, Sharma SK, Panneerselvam A, Singh K, Parmar G, Gadge Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:251-260. Available from: https://doi.org/10.2147/dmso.s106133
  19. Nickerson H, Dutta Diabetic complications: Current challenges and opportunities. Curr Atheroscler Rep. 2012;5(4):375-379. Available from: https://doi.org/10.1007/s12265-012-9388-1
  20. Παπαθεοδώρου K, Banach M, Bekiari E, Rizzo M, Edmonds Complications of diabetes 2017. J Diabetes Res. 2018;2018:1-4. Available from: https://doi.org/10.1155/2018/3086167
  21. Currie CJ, Peyrot M, Morgan CL, Poole C, Jenkins-Jones S, Rubin RR, et The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279-1284. Available from: https://doi.org/10.2337/ dc11-1277
  22. Lin YC, Lü M, Tang HL, Liu HC, Chen C, Liu KS, et al. Assessment of hypermucoviscosity as a virulence factor for experimental Klebsiella pneumoniae infections: Comparative virulence analysis with hypermucoviscosity-negative strain. BMC Microbiol. 2011;11(1):50. Available from: https://doi. org/10.1186/1471-2180-11-50
  23. Blackburn D, Swidrovich J, Lemstra Nonadherence in type 2 diabetes: Practical considerations for interpreting the literature. Patient Prefer Adherence. 2013;7:183-190. Available from: https:// doi.org/10.2147/ppa.s30613
  24. Herman WH, Zimmet Type 2 diabetes: An epidemic requiring global attention and urgent action. Diabetes Care. 2012;35(5):943- 944. Available from: https://doi.org/10.2337/dc12-0298
  25. Kirkman MS, Rowan-Martin MT, Levin R, Fonseca V, Schmittdiel JA, Herman WH, et al. Determinants of adherence to diabetes medications: Findings from a large pharmacy claims database. Diabetes Care. 2015;38(4):604-609. Available from: https://doi.org/10.2337/dc14-2098
  26. Poor medication adherence in type 2 diabetes: Recognizing the scope of. Patient Prefer Adherence. 2016;10:1067-1075. Available from: https://doi.org/10.2147/PPA.S106821
  27. Blackburn D, Swidrovich J, Lemstra Nonadherence in type 2 diabetes: Practical considerations for interpreting the literature. Patient Prefer Adherence. 2013;7:183-190. Available from: https:// doi.org/10.2147/ppa.s30613
  28. Pilla SJ, Mathioudakis N, Maruthur NM. Trialing precision medicine for type 2 diabetes. Nat Med. 2023;29(2):309-310. Available from: https://doi.org/10.1038/s41591-022-02168-5
  29. Poor medication adherence in type 2 diabetes: Recognizing the scope of. Patient Prefer Adherence. 2016;10:1067-1075. Available from: https://doi.org/10.2147/PPA.S106821
  30. Dhindsa DS, Sandesara PB, Shapiro MD. The intersection of diabetes and cardiovascular disease—A focus on new Front Cardiovasc Med. 2018;5:160. Available from: https://doi. org/10.3389/fcvm.2018.00160
  31. Hendra Review: Diabetes and insulin therapy in older people. Rev Diabet Stud. 2005;2(1):12-16. Available from: https://doi.org/10.1177/14746514050050010401
  32. American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: Standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1) Available from: https://doi.org/10.2337/dc19-S001
  33. Delamater AM. Improving patient adherence. Clin Diabetes. 2006;24(2):71-77. Available from: https://doi.org/10.2337/ 24.2.71
  34. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314-322. Available from: https://doi.org/10.1111/j.1742-2010.02544.x
  35. García-Pérez L, Daca-Álvarez M, Dilla T, Gil-Guillén VF, Orozco-Beltrán D. Adherence to therapies in patients with type2 diabetes. Diabetes Ther. 2013;4(2):175-194. Available from: https://doi.org/10.1007/s13300-013-0034-y
  36. Poor medication adherence in type 2 diabetes: Recognizing the scope of. Patient Prefer Adherence. 2016;10:1067-1075. Available from: https://doi.org/10.2147/PPA.S106821
  37. Asche CV, LaFleur J, Conner A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74-109. Available from: https:// doi.org/10.1016/j.clinthera.2011.01.019
  38. Henry DP, Weng H, Paek Poor medication adherence in type 2 diabetes: Recognizing the scope of. Patient Prefer Adherence. 2016;10:1067-1075. Available from: https://doi.org/10.2147/ppa. s106821
  39. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1) Available from: https://doi.org/10.2337/dc14- S014
  40. WikiDoc. 2012. Available from: https://www.wikidoc. org/index.php/Insulin
  41. Nkole Discussing diabetes. 2023.
  42. Frid A, Hirsch L, Gaspar R, Hicks D, Kreugel G, Liersch J, et al. New injection recommendations for patients with diabetes. Diabetes 2010;36(Suppl 3) Availablefrom: https:/sciencedirect.com/science/article/pii/S1262363610700021
  43. Korat AV, Willett WC, Hu FB. Diet, lifestyle, and genetic risk factors for type 2 diabetes: A review from the Nurses’ Health Study, Nurses’ Health Study 2, and Health Professionals’ Follow-Up Curr Nutr Rep. 2014;3(4):345-354. Available from: https://doi.org/10.1007/s13668-014-0103-5
  44. Managing employee absenteeism. FindLaw. 2016. Available from: https://corporate.findlaw.com/human-resources/managing- employee-absenteeism.html
  45. Swift CO, Wayland JP, Wayland The impact of the Americans with Disabilities Act (ADA) on customer relationships. J Retailing Consumer Services. 1997;3(4):81-87. Available from: https://doi.org/10.1300/j127v03n04_07
  46. Medical Assistant Training in NJ – Healthcare Training Healthcare Training Institute. 2015.
  47. Design SS. Press release: NewYork-Presbyterian undertaking extensive accessibility enhancements benefiting patients with disabilities. New York Lawyers for the Public Interest. 2024. Available from: https://nylpi.org/press-release- newyork-presbyterian-undertaking-extensive-accessibility- enhancements-benefiting-patients-with-disabilities/
  48. Light J, McNaughton D, Beukelman DR, Fager S, Fried-Oken M, Jakobs T, et Challenges and opportunities in augmentative and alternative communication: Research and technology development to enhance communication and participation for individuals with complex communication needs. Augment Altern Commun. 2019;35(1):1-12. Available from: https://doi.org/10.108 0/07434618.2018.1556732
  49. Why is healthcare compliance so Google Sites. 2023. Available from: https://sites.google.com/view/why-is-healthcare- compliance/home
  50. Health Care Workers and the Americans with Disabilities Act. U.S. Equal Employment Opportunity Commission. 2007. Available from: https://eeoc.gov/laws/guidance/health- care-workers-and-americans-disabilities-act